Newsroom
Top Results
Sight Sciences Appoints Donald J. Zurbay to Company’s Board of Directors
Highly accomplished industry executive brings financial and operational expertise to innovative eye care company
Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires
Industry veterans will lead scaling of company operations and processes to support OMNI Surgical System and TearCare growth
Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology
Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D.
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners
MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and […]
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial
Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study […]
Sight Sciences Announces the Closing of its $7MM Series B Financing Led by Hicks Equity Partners
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed a $7 million Series B round of financing. The round was led by Hicks Equity Partners, a leading private equity firm based in Dallas, Texas. All Series A investors participated in the oversubscribed Series B round, including Scientific Health […]
Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include Anne-Marie Ripley, Vice President of Clinical and Regulatory Affairs, Ingrid Kane, M.D., Vice President of Global Medical Affairs, Jamie Chakales, Vice President of Global Sales […]
Sight Sciences Secures $10MM in Oversubscribed Series C Financing
Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with a seasoned ophthalmic industry veteran. Allegro Investment Fund, a privately held fund based in Menlo Park, CA, led the round with full participation from all existing […]